I. Wagner

Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study

M. Sinn, S. Kasper, K. Caca, 2019, Annals of Oncology.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

D. Niederwieser, R. Rohrberg, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

D. Niederwieser, T. Lindner, W. Pönisch, 2012, Journal of Cancer Research and Clinical Oncology.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.

R. Dummer, P. Hilfiker, M. L. Veronese, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Bendamustine Pretreatment on Stem Cell Mobilization and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

H. Goldschmidt, D. Niederwieser, U. Hegenbart, 2011 .

Successful Treatment with Bortezomib in Combination with Bendamustine and Prednisone of Patients with Newly Diagnosed/Untreated Multiple Myeloma and Light Chain Induced Renal Failure

D. Niederwieser, T. Lindner, W. Pönisch, 2011 .

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.